1921
Volume 75, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

During 1996 through 2004, 29 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been reported worldwide; 17 were fatal. Stress-dose corticosteroid (SDS) therapy has recently been found to improve survival among patients with septic shock but benefit for the treatment of YEL-AVD patients in septic shock is unknown. We retrospectively reviewed medical records of 11 U.S. YEL-AVD cases reported to the Vaccine Adverse Event Reporting System (VAERS) from 1996 through 2004. Four of 11 case-patients received SDS; 3 of these 4 (75%) survived. Seven patients did not receive SDS and 2 (29%) survived. Altered mental status was documented on admission for 5 of the 11 patients; 4 of these 5 did not receive SDS and died, whereas one received SDS and survived. The use of stress-dose steroids might be a factor that influenced the survival of these YEL-AVD patients and should be further evaluated in the management of both YEL-AVD and wild-type yellow fever septic shock.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2006.75.333
2006-08-01
2017-03-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/2/0750333.html?itemId=/content/journals/10.4269/ajtmh.2006.75.333&mimeType=html&fmt=ahah

References

  1. World Health Organization, fact sheet no. 100. Yellow Fever. 2001. Available at: http://www.who.int/topics/yellow_fever/en. Accessed October 11, 2005.
  2. Monath TP, 2001. Yellow Fever: An Update. Lancet Infect Dis 1 : 11–20.
  3. Monath TP, Tsai TF, 1997. Flaviviruses. Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. New York: Churchill-Livingstone, 1133.
  4. Tsai TF, Vaughn DW, Solomon T, 2005. Flaviviruses (Yellow Fever, Dengue, Dengue Hemorrhagic Fever, Japanese Encephalitis, West Nile Encephalitis, St. Louis Encephalitis, Tick-Borne Encephalitis). Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Sixth edition. Philadelphia: Churchill Livingstone, Inc., 1927–1951.
  5. Monath TP, 2003. Yellow fever. Plotkin SA, Orenstein WA, eds. Vaccines. Fourth Edition. Philadelphia: W. B. Saunders, 1095–1176.
  6. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani JT, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66 : 533–541.
  7. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP, 2005. Randomized Double-blind, Phase III, Pivotal Field Trial of the Comparative Immunogenicity, Safety, and Tolerability of Two Yellow Fever 17D Vaccines (Arilvax and YF-VAX) in Healthy Infants and Children in Peru. Am J Trop Med Hyg 72 : 189–197.
  8. Advisory Committee on Immunization Practices, 2002.Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2002. Morbidity and Mortality Weekly Report 51 : 1–12.
  9. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS, GeoSentinel Yellow Fever Working Group, 2001. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7 : 94–95.
  10. Barwick RS, 2004. History of Thymoma and Yellow Fever Vaccination. Correspondence in the Lancet 364 : 936.
  11. Chen RT, Rastogi SC, Mullen JR, 1994. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12 : 542–550.
  12. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived Yellow Fever vaccination—United States, 2001–2002. Morbidity and Mortality Weekly Report 51 (44): 989–993.
  13. Martin M, Tsai TF, Cropp B, Chang GJJ, Holmes DA, Tseng J, Shieh WJ, Zaki SR, As-Sanouri I, Cutrona AF, Ray G, Weld LH, Cetron MS, 2001. Fever and multisystem organ failure associated with 17D-204 Yellow Fever vaccination: a report of four cases. Lancet 358 : 98–104.
  14. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E, 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 : 862–871.
  15. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, 2004. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 : 858–873.
  16. Munford RS, 2005. Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Sixth edition. Philadelphia: Churchill Livingstone, Inc., 906–924.
  17. Annane D, Bellisant E, Cavaillon JM, 2005. Septic shock. Lancet 365 : 63–78.
  18. Minneci PC, Deans KJ, Banks SM, Elchacker PQ, Natanson C, 2004. Meta-Analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141 : 47–56.
  19. World Health Organization, WHO/AFRO Yellow Fever. 2004. Available at: http://www.afro.who.int/yellowfever/. Accessed October 11, 2005.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.333
Loading
/content/journals/10.4269/ajtmh.2006.75.333
Loading

Data & Media loading...

  • Received : 03 Jan 2006
  • Accepted : 19 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error